Dany Obeid, MD
Pulmonary Disease · Daytona Beach, FLNPI 1841336310
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $136,325 of the $163,308 with a category attached, or 83.5%. GSK accounts for 90.5% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2019 at $33,407 and has fallen 88.0% since, to $4,011 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 662 payments — averaging $246.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$148K
- Intuitive Surgical$3K
- Boehringer Ingelheim$1K
- AstraZeneca$1K
- Olympus Corporation Of The Americas$1K
- Jazz Pharmaceuticals Inc.$949
- plus $8K from 41 others
Across 35 payments — averaging $10,599 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$146K
- Mylan Specialty L.p.$91K
- AstraZeneca$63K
- GSK$44K
- Roche Products Limited$21K
- Chiesi USA, Inc.$6K
Across 4 payments — averaging $12,500 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$50K
What the payments were for
- Consulting fees$6,1754%
- Speaking & faculty fees$136,32583%
- Travel & lodging$4,5063%
- Food & beverage$13,1128%
- Education$3,1902%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$107,470
- ION$3,000
- Da Vinci Surgical System$390
- DUPIXENT$121
- FASENRA$113
- BREZTRI$113
- FARXIGA$113
How this compares
$163,308 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 872 | $833,244 |
| XywavSodium,calcium,mag,pot Oxybate | 11 | $221,576 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 19 | $180,458 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 342 | $176,833 |
| OfevNintedanib Esylate | 14 | $173,348 |
| Breo ElliptaFluticasone/Vilanterol | 206 | $137,359 |
| Dupixent PenDupilumab | 28 | $102,621 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $77,393 |
| Spiriva RespimatTiotropium Bromide | 66 | $65,586 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 85 | $63,661 |
| SymbicortBudesonide/Formoterol Fumarate | 72 | $22,375 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $19,279 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 517 | $17,497 |
| Roflumilast | 133 | $15,062 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $9,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $147,788 | $1,156,9141,434 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,293 | $302,594165 claims |
| Grifols USA, LLCProlastin C | $867 | $180,45819 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,279 | $99,768145 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $48 | $1,08714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Daytona Beach
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.